An emerging number of studies [38,68,69] suggest that epigenetic reprogramming of EMT via EZH2 inhibitors could promote anticancer effects, as EMT induction poses a significant challenge in the management of HPV-associated cancers, severely impacting efforts to extend patient survival. This evidence concerns the gene EZH2 and cancer.